Gapping up
In reaction to earnings/guidance:
- TITN +13.5%, BOX +8.9%, ANF +8.7%, NTAP +7.5%, FLWS +5.9%, SAFM +4.1%, CM +3%, MESO +2.6%, LANC +2.1%, DG +1.5%, TIF +1.4%, ESTC +1.1%, FRO +1.1%
M&A news:
- BMCH +13.4% (Builders Firstsource (BLDR) and BMC Stock Holdings (BMCH) to merge); BLDR +1.1%
Other news:
- CLVS +16.1% (receives FDA approval for FoundationOne Liquid CDx to serve as Rubraca (rucaparib) companion)
- ABT +9% (receives FDA Emergency Use Authorization for 15-minute COVID-19 Antigen test)
- PSTI +7.3% (FDA cleared the company's EAP for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19 outside of the company's ongoing Phase II COVID-19 study in the U.S)
- GPRE +4% (granted motion to be dismis from lawsuit)
- RDHL +2.4% (announced that its U.S. Phase 2 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, has successfully passed the first scheduled independent Safety Monitoring Committee review)
- AMC +1.7% (to reopen additional 170 theatres)
- CCL +1.2% (extends pause in cruise operations in Australia and New Zealand)
- IGT +1% (expands PlaySports offering)
- BCO +1% (enters accelerated share repurchase agreement to buy $50 mln of the company's common stock)
Analyst comments:
- MGY +3.8% (upgraded to Overweight from Equal Weight at Barclays)
- ARCB +3.4% (initiated with a Buy at Goldman)
- APA +1.7% (upgraded to Outperform from In-line at Evercore ISI)
- SQ +1.4% (initiated with a Buy at Mizuho)
- EV +1.2% (upgraded to Overweight from Neutral at JP Morgan)